A recently published analysis evaluates the value proposition of an innovative vaccine delivery technology in development, a microarray patch (MAP), that could be used to extend the reach of vaccines to hard-to-reach populations and increase vaccine uptake and coverage. The analysis evaluated the potential cost-effectiveness of typhoid conjugate vaccine microarray patches (TCV-MAPs) alongside administration with a needle and syringe compared to needle and syringe delivery alone. The analysis covered 133 low- to upper-middle-income countries for the time horizon of 20 years (2033–2052).
The findings showed that national rollouts of TCV-MAPs could avert an additional 5.2 million cases, 47,000 deaths, and 2.4 million DALYs compared to needle and syringe delivery only, at an additional cost of US$3.5 billion over 20 years. The largest proportion of the averted burden would be in the sub-Saharan African region. TCV-MAPs could be cost-effective in 33 % of the countries but in 78 % of sub-Saharan African countries.
This evaluation demonstrates that TCV-MAPs have the potential to be cost-effective in countries within sub-Saharan Africa due to the higher typhoid disease burden but are less likely to be cost-effective in most countries outside this region. The results of the analysis help identify the key variables impacting the potential cost-effectiveness of TCV-MAPs which can support ongoing development and decision making for this this novel technology.
Thumbnail image credit: Gavi/2018
Any organization or individual working in the field of immunization economics can submit findings, opportunities, calls to action, or other relevant work below to be shared with our community.